Dr. Sara M. Tolaney

Additional Advances in Triple-Negative Breast Cancer Research and Trials: Sara M. Tolaney, MD, MPH

Oncology Data Advisor

Sara M. Tolaney, MD, MPH discusses the TAILORx study

Dr Sara M. Tolaney: Challenges With Treating, Role of Clinical Trials in HER2-Positive Breast Cancer

Dr Sara M. Tolaney Discusses the Role of Adjuvant Therapy in HER2-Positive Breast Cancer

Dr. Sara M. Tolaney on Neoadjuvant Treatment Considerations for TNBC

Dr Sara M. Tolaney: Standard of Care, Novel Approaches For Treatment of HER2-Positive Breast Cancer

SABCS22: Sara Tolaney, MD, MPH | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Using clinical trials in treatment: Dr. Sara Tolaney | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

Sara Tolaney, ESMO 2022: Clinical trial highlights in breast cancer

Touch Medical Media Services

Expert Perspectives in the Management of Triple-Negative Breast Cancer With Sara Tolaney, MD, MPH

Oncology Data Advisor

Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast Cancer

Sara Tolaney, SABCS 2022: Adjuvant paclitaxel and trastuzumab for node-negative HER2+ breast cancer

Touch Medical Media Services

Sara M. Tolaney on Neoadjuvant Treatment Considerations for Triple-Negative Breast Cancer

Sara M. Tolaney, MD, MPH, shares outcomes from the ImPassion130 study in TNBC

Sara M. Tolaney, MD, MPH, provides an overview of the results from the SOPHIA trial

Expert Perspectives in the Management of TNBC: a Webinar Preview With Sara Tolaney, MD, MPH

Oncology Data Advisor

Sara M. Tolaney, MD, MPH, shares outcomes from the MONALEESA-7 trial

ASCO22: Breast cancer research by Sara Tolaney, MD | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Breast Cancer ASCO 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Sara Tolaney

OncBrothers: Practice-Changing Cancer Discussions